Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects
about
The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasisRecent developments and future prospects in the treatment of visceral leishmaniasisAntituberculosis therapy for 2012 and beyondNitroimidazoles for the treatment of TB: past, present and futureStrategies for treating latent multiple-drug resistant tuberculosis: a decision analysisRapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamidePharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosisMolecular insights into the binding of coenzyme F420 to the conserved protein Rv1155 from Mycobacterium tuberculosis.Insights into the pharmacokinetic properties of antitubercular drugs.The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis.Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs.Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patientsCross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial Discovery.Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human liver.PA-824 exhibits time-dependent activity in a murine model of tuberculosis.Design, synthesis, and study of a mycobactin-artemisinin conjugate that has selective and potent activity against tuberculosis and malariaImpact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824.Drug-resistant tuberculosis: emerging treatment options.Current development and future prospects in chemotherapy of tuberculosisMutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosisPhase II dose-ranging trial of the early bactericidal activity of PA-824New drugs and regimens for treatment of TB.Design and Synthesis of Molecular Scaffolds with Anti-infective Activity.Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimenEffect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects.Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects.Emerging drugs for the treatment of tuberculosis.The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies.Tuberculosis drugs: new candidates and how to find more.New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future.Antituberculosis drug research: a critical overview.Prospects for new antibiotics: a molecule-centered perspective.Resistance in tuberculosis: what do we know and where can we go?Investigational drugs for visceral leishmaniasis.The anti-tuberculosis agents under development and the challenges ahead.Drug Resistance Mechanisms in Mycobacterium tuberculosis.Encapsulation of Anti-Tuberculosis Drugs within Mesoporous Silica and Intracellular Antibacterial Activities.Nitroimidazooxazoles(#) Part xxiv, Search for Antileishmanial Agents: 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles as Potential Antileishmanial Agents.A class of 5-nitro-2-furancarboxylamides with potent trypanocidal activity against Trypanosoma brucei in vitro.
P2860
Q24633734-12D69E62-018B-43A0-83AA-D3E954B0BB13Q26740563-4290E472-74A1-40AF-865A-50A2947A1312Q26829101-8ED97E4D-12D6-402E-89BB-82B96A87FD6EQ26849554-E0ADAE03-49FC-4C3E-8E84-470FB339F762Q28478920-2F53EB03-98C0-446B-A658-E014E65B3B3FQ28478966-EF2E7674-D6E5-44FA-9C59-EB707E36C6B9Q28542435-5488E42D-5616-401D-979B-12683AACA5F7Q29568187-4B71C8B0-BA7A-4316-9B81-5D4F8B049978Q30251497-67F2B51E-D0A1-41DF-8907-5B09270A2804Q30447200-497E7D41-1147-4F1D-837A-11609CB1D112Q33768799-6862CDE4-E154-4503-9842-D6D9D0665D7AQ34045233-B0ECBD5A-CF2B-48D1-B869-90B60C6CE739Q34113517-36AA0024-A440-4F27-B4BD-7AF29DB60026Q34410451-838D5119-ACB5-4B5B-AFCA-ED228CCDFDECQ34449746-07D92975-2ECC-4C19-A8D9-05D408AA2CEBQ34483632-15AF3CAE-4CDE-4C91-BF6A-CAC99002AA24Q34609996-E71A23B3-ADA8-422B-BE3A-8B42A0AF01B6Q35598383-462A3F0C-970C-49E5-851C-818F3388FE57Q35683967-63189FC9-3489-45CE-9222-491B12CF314BQ35705874-56875C3A-6A9D-4316-9D13-2B3104D1A88EQ35960987-E8DF9C71-43FB-4648-A915-6A645F75BF30Q36018781-23B166B3-71CB-4531-AB4A-2566ADF5ECADQ36825354-B2DD7E1E-8CE1-4D37-8ACB-26420E186F4AQ36972421-5F1B6DA3-9802-4054-B5FB-61004F20B468Q37036499-18230E24-D194-4F51-BA89-3445B122B8C1Q37263381-F774ACB6-EE9D-4B4A-B3C3-868F89E215CFQ37333140-D499152D-9879-4238-8371-62AB98058D4BQ37792105-686D17C4-1ADE-44D7-843D-D77DC38FBDFFQ37855837-03D3127E-1842-4FE2-8CC1-4B2A98D83BC7Q37894691-038007C7-21EF-4499-9424-8D1A0B7B1BFCQ37996998-8621038E-8134-453B-8D17-9551D111FC89Q38012651-AAF934D6-382A-43E0-A545-6EF7AFE002FEQ38113689-1B97A306-C1DF-48B9-87C8-47CFEF589655Q38124261-76A77042-894B-463F-9379-67CB6A47B803Q38269581-354DB0F9-716E-4FFD-BA34-3EE29F0E6DC1Q38617197-ECDB4C5E-01D1-4E91-949D-7222C86AFB9EQ38792870-9A1FD011-01E9-402A-B70C-A1228CE96D96Q38875308-E2F87D5D-BB85-4CBB-B4E5-CEC89B11DAEDQ39141424-025B5A50-F553-4E1F-8D3A-B92936A664A2Q39492522-A0C8BB93-4B10-4E6A-9FE6-D88EC33B5B8F
P2860
Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects
@ast
Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects
@en
Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects
@nl
type
label
Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects
@ast
Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects
@en
Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects
@nl
prefLabel
Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects
@ast
Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects
@en
Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects
@nl
P2093
P2860
P356
P1476
Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects
@en
P2093
Ann M Ginsberg
Doris J Rouse
Karl D Whitney
Martino W Laurenzi
Melvin K Spigelman
P2860
P304
P356
10.1128/AAC.00106-09
P407
P577
2009-09-01T00:00:00Z